asthma
Respiratory · 2007–2025
44decisions
23medicines
25carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dupilumab Treatment of severe atopic dermatitis in patients aged less than 12 years, and uncontrolled severe asthma in patients aged 6 to 11 years. | Mar 2025 | Recommended with restriction | input received |
| omalizumab New formulations (pre-filled pen and pre-filled syringe with safety device) and new 300 mg/2 mL strength of omalizumab for the treatment of uncontrolled severe… | Mar 2025 | Recommended with restriction | input received Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate Maintenance and reliever therapy (MART) for asthma in adults (18 years and older) with frequent asthma symptoms despite treatment with inhaled corticosteroids… | Mar 2024 | Recommended with restriction | input received Asthma Australia · National Asthma Council Australia |
| dupilumab Treatment of patients aged 6 to 11 years with uncontrolled severe asthma who have elevated IgE (≥30 IU/mL with evidence of atopy) and/or blood eosinophils… | Mar 2024 | Recommended with restriction | input received Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| mepolizumab Treatment of uncontrolled severe asthma (including severe eosinophilic asthma) in patients aged 12 years and over. | Mar 2024 | Recommended with restriction | 1 individuals |
| tiotropium Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in… | Nov 2024 | Recommended | input received Lung Foundation Australia |
| budesonide with formoterol Treatment of asthma (mild asthma, asthma in patients with frequent episodes or requiring maintenance and reliever therapy, and asthma in patients who have… | Nov 2023 | Recommended | input received Asthma Australia |
| fluticasone propionate with salmeterol Treatment of asthma in patients aged 4 years or older; treatment of chronic obstructive pulmonary disease (COPD) in patients with severe COPD and a history of… | Nov 2023 | Recommended | input received Asthma Australia |
| beclometasone with formoterol Maintenance treatment of asthma in adults aged 18 years and older who are not adequately controlled with inhaled corticosteroids and 'as needed' inhaled… | Jul 2022 | Recommended with restriction | input received Asthma Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate and glycopyrronium Maintenance treatment of severe asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta-2 agonist and an… | Mar 2022 | Recommended with restriction | input received Asthma Australia |
| dupilumab Chronic severe atopic dermatitis and uncontrolled severe asthma in patients aged 12 years and older. A new autoinjector formulation (200 mg in 1.14 mL and 300… | Nov 2022 | Recommended | input received Asthma Australia |
| fluticasone furoate / umeclidinium / vilanterol Maintenance treatment of severe asthma in adults who are not adequately controlled with a combination of inhaled corticosteroid and long-acting beta2 agonist. | Nov 2021 | Recommended with restriction | input received |
| omalizumab Request to combine existing PBS listings of omalizumab 75 mg and 150 mg pre-filled syringes to allow patients requiring doses of 225 mg or 375 mg to pay a… | Nov 2021 | Not recommended | input received |
| beclometasone dipropionate with formoterol fumarate dihydrate Maintenance treatment of asthma and maintenance and reliever therapy (MART) in adults (18 years and older) not adequately controlled with inhaled… | Jul 2020 | Recommended with restriction | input received National Asthma Council · Asthma Australia |
| mometasone furoate with indacaterol and glycopyrronium Maintenance therapy of severe asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled… | Jul 2020 | Recommended with restriction | input received Asthma Australia |
| mometasone furoate with indacaterol Maintenance treatment of asthma in patients aged 12 years and older who have previously had frequent episodes of asthma while receiving treatment with oral… | Jul 2020 | Recommended with restriction | input received Asthma Australia |
| tiotropium Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in adults and children aged 6–17 years. | Jul 2020 | Recommended | 1 individuals Lung Foundation · Asthma Australia |
| salbutamol Relief of acute bronchospasm in patients with asthma and other obstructive airways diseases. Specifically, a pressurised inhalation formulation with integrated… | Mar 2020 | Recommended with restriction | no section in document |
| budesonide with formoterol Treatment of asthma in adolescents and adults aged 12 years and over with mild asthma who are uncontrolled on short-acting beta2-agonist (SABA) as needed or… | Jul 2019 | Not recommended | 1 individuals Asthma Australia |
| fluticasone furoate Maintenance treatment of asthma in children aged 5 to 11 years. | Jul 2019 | Recommended | input received |
| budesonide + formoterol Asthma in children aged <12 years who have failed PBS-subsidised fluticasone propionate and salmeterol as a fixed dose combination. | Dec 2019 | Recommended with restriction | no section in document |
| budesonide with formoterol Mild asthma in adolescents and adults (aged 12 years or over) for use as an anti-inflammatory reliever therapy administered as needed. | Nov 2019 | Recommended with restriction | unclear |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma in adults with frequent asthma episodes or symptoms despite oral corticosteroids, inhaled corticosteroids, or combination ICS/LABA therapy;… | Aug 2018 | Recommended | none received |
| tiotropium Severe asthma in children aged 6 to 17 years who remain uncontrolled despite receiving optimised asthma therapy (high-dose inhaled corticosteroid plus… | Mar 2018 | Not recommended | input received Asthma Australia |
| fluticasone propionate with formoterol fumarate dihydrate Regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2-agonist) is appropriate, in… | Nov 2018 | Not recommended | none received |
| tiotropium Add-on maintenance bronchodilator treatment for children and adolescents aged 6-17 years with severe asthma who have failed to achieve adequate control despite… | Nov 2018 | Recommended with restriction | input received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients aged 18 years and over. | Jul 2017 | Not recommended | input received |
| tiotropium Add-on maintenance bronchodilator treatment in adult patients with severe asthma who are currently treated with inhaled corticosteroids and long-acting beta-2… | Jul 2017 | Not recommended | none received |
| fluticasone furoate Maintenance treatment of asthma in patients aged ≥12 years. | Mar 2017 | Recommended | none received |
| budesonide with eformoterol fumarate dihydrate Asthma in patients aged 18 years and over with frequent episodes or symptoms despite treatment with oral corticosteroids, inhaled corticosteroids, or… | Nov 2017 | Recommended | none received |
| tiotropium Add-on maintenance bronchodilator treatment in adult patients with severe asthma who are currently treated with maintenance combination of inhaled… | Nov 2017 | Not recommended | no section in document |
| tiotropium Add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids… | Mar 2016 | Recommended with restriction | input received National Asthma Council Australia |
| fluticasone propionate with salmeterol xinafoate Treatment of asthma in adults with frequent episodes despite oral corticosteroids or optimal inhaled corticosteroid doses, and symptomatic treatment of severe… | Nov 2016 | Not recommended | input received Thoracic Society · National Asthma Council Australia · Asthma Australia |
| salbutamol Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients unable to use salbutamol delivered from an oral pressurised inhalation device… | Nov 2016 | Recommended | none received |
| tiotropium bromide Add-on maintenance bronchodilator treatment in adult patients with severe persistent asthma who are currently treated with the maintenance combination of… | Jul 2015 | Not recommended | input received Lung Foundation |
| fluticasone furoate Maintenance treatment of asthma in patients aged 12 years and over. Available in two strengths: 100mcg once daily (mid-dose) and 200mcg once daily (high-dose). | Nov 2015 | Recommended | none received |
| fluticasone furoate / vilanterol trifenatate Regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2 agonist and inhaled… | Mar 2014 | Recommended | unclear |
| salbutamol New pack size (128 capsules) of salbutamol for inhalation to replace the current 100 capsule pack due to supply difficulties. | Nov 2014 | Recommended | no section in document |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma (maintenance and SMART regimen) and chronic obstructive pulmonary disease (COPD) in adults and adolescents. | Jul 2013 | Recommended | no section in document |
| fluticasone propionate with eformoterol fumarate Regular maintenance treatment of asthma in patients whose asthma is not adequately controlled with inhaled corticosteroids alone or who require combination… | Jul 2013 | Recommended | no section in document |
| salbutamol sulfate patients who are unable to achieve coordinated use of other metered dose inhalers containing salbutamol or patients at risk of an acute asthma episode | Mar 2010 | Not recommended | no section in document |
| montelukast sodium Prevention of exercise-induced asthma, as an alternative to adding salmeterol xinafoate or eformeterol fumarate in children aged 6 to 14 years whose asthma is… | Jul 2009 | Recommended with restriction | no section in document |
| budesonide with eformoterol fumarate dihydrate For single maintenance and reliever therapy in patients who experience asthma symptoms while receiving treatment with oral or inhaled corticosteroids; for… | Mar 2007 | Recommended with restriction | no section in document |
| budesonide with eformoterol fumarate dihydrate Single maintenance and reliever therapy in patients who experience frequent asthma symptoms while receiving treatment with oral corticosteroids, inhaled… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Asthma Australia · National Asthma Council Australia · National Allergy Council · Anaphylaxis Australia · Lung Foundation · National Asthma Council · Thoracic Society · Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 25 of 38 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.